We were delighted to talk to Jean-Luc Van Laethem (Hôpital Universitaire Erasme, Université Libre de Bruxelles, Brussels, Belgium) around pembrolizumab therapy in patients with previously untreated advanced hepatocellular carcinoma (Clinical Trial Identifier: NCT02702414).
The abstract ‘Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study’ (ABSTRACT NUMBER: 297) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
Questions
- What is the current status of pembrolizumab in the treatment of patients with advanced hepatocellular carcinoma (HCC), and how will the findings of KEYNOTE-224 impact on future research? (0:39)
- Which patients are most likely to respond to pembrolizumab therapy? (2:35)
Disclosures: Jean-Luc Van Laethem has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
